JP2014503537A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503537A5
JP2014503537A5 JP2013545218A JP2013545218A JP2014503537A5 JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5 JP 2013545218 A JP2013545218 A JP 2013545218A JP 2013545218 A JP2013545218 A JP 2013545218A JP 2014503537 A5 JP2014503537 A5 JP 2014503537A5
Authority
JP
Japan
Prior art keywords
cancer
breast cancer
positive
treatment
body according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545218A
Other languages
English (en)
Japanese (ja)
Other versions
JP5886873B2 (ja
JP2014503537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/073041 external-priority patent/WO2012084711A1/en
Publication of JP2014503537A publication Critical patent/JP2014503537A/ja
Publication of JP2014503537A5 publication Critical patent/JP2014503537A5/ja
Application granted granted Critical
Publication of JP5886873B2 publication Critical patent/JP5886873B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013545218A 2010-12-24 2011-12-16 Ｎ置換アゼチジン誘導体 Expired - Fee Related JP5886873B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10196960 2010-12-24
EP10196960.8 2010-12-24
PCT/EP2011/073041 WO2012084711A1 (en) 2010-12-24 2011-12-16 N-substituted azetidine derivatives

Publications (3)

Publication Number Publication Date
JP2014503537A JP2014503537A (ja) 2014-02-13
JP2014503537A5 true JP2014503537A5 (cg-RX-API-DMAC10.html) 2014-08-21
JP5886873B2 JP5886873B2 (ja) 2016-03-16

Family

ID=43778253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545218A Expired - Fee Related JP5886873B2 (ja) 2010-12-24 2011-12-16 Ｎ置換アゼチジン誘導体

Country Status (7)

Country Link
US (1) US9540361B2 (cg-RX-API-DMAC10.html)
EP (1) EP2655367B1 (cg-RX-API-DMAC10.html)
JP (1) JP5886873B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011347718B2 (cg-RX-API-DMAC10.html)
CA (1) CA2819299A1 (cg-RX-API-DMAC10.html)
ES (1) ES2586908T3 (cg-RX-API-DMAC10.html)
WO (1) WO2012084711A1 (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
NZ710385A (en) 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016174551A1 (en) * 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
JP6920295B2 (ja) * 2015-11-09 2021-08-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
DK3386500T3 (da) 2015-12-09 2022-12-12 Univ Illinois Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
SG11201806829TA (en) * 2016-02-15 2018-09-27 Sanofi Sa 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
UA125824C2 (uk) * 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
EP3541809B1 (en) 2016-11-17 2025-06-25 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3645001B1 (en) 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
KR102765922B1 (ko) * 2018-02-06 2025-02-11 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
EP4681715A3 (en) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
MX2022010425A (es) 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
EP4164653A4 (en) 2020-06-15 2024-06-19 G1 Therapeutics, Inc. MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
GB202015187D0 (en) 2020-09-25 2020-11-11 Sentinel Oncology Ltd A pharmaceutical salt
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
CN113248455A (zh) * 2021-05-25 2021-08-13 湖北科技学院 一种3,5-二取代异噁唑类衍生物及其合成方法
BR112023024507A2 (pt) 2021-05-26 2024-02-15 C4 Therapeutics Inc Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
WO2023059714A1 (en) * 2021-10-06 2023-04-13 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
KR20250055538A (ko) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Ret 단백질을 조정하기 위한 화합물
CN117924262A (zh) * 2022-10-14 2024-04-26 中国科学院上海药物研究所 二氢苯并噻喃类衍生物及其制备方法和用途
JP2025540906A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質阻害剤
KR20250117789A (ko) 2022-11-04 2025-08-05 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 분해제
CN116813603B (zh) * 2023-06-02 2024-10-22 成都市第三人民医院 一种选择性雌激素受体α降解化合物及其制备方法和应用
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
TW200304371A (en) * 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
US20030225132A1 (en) 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
ATE481397T1 (de) 2002-04-24 2010-10-15 Merck Sharp & Dohme Modulatoren des östrogenrezeptors
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation

Similar Documents

Publication Publication Date Title
GT201500206A (es) Modulador del receptor de andrógeno y usos de este
IL208844A0 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer, etc
MX367624B (es) Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática.
MX2010005221A (es) Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
IL252766A0 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
SG11201603462SA (en) Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
HK1221424A1 (zh) 治疗癌症的药物组合
IL247093A0 (en) Progesterone antagonists such as 4124–cdb in the treatment of breast cancer
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX368234B (es) Conjugados de anticuerpo-fármaco (adcs) que contienen duocarmicina para usarse en el tratamiento de cáncer endometrial.
PH12013501127A1 (en) Use of sigma ligands in bone cancer pain
NI201200071A (es) Nuevo uso antitumoral de cabazitaxel
PH12016501550B1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
LT3324994T (lt) Nx-1207, skirtas panaudoti chirurgijos poreikio sumažinimo metode pacientams, sergantiems gerybine prostatos hiperplazija
NZ626736A (en) Phragamalin limonoids for the treatment of sexual dysfunction
MX2015016550A (es) Antagonistas de imidazolil progesterona.
CL2011002774A1 (es) Combinacion farmaceutica que comprende cabazitaxel y capecitabina, en forma de base, sal, hidrato o solvato; uso para el tratamiento del cancer de mama metastasico.
PH12012501812A1 (en) Compositions and methods for non-toxic delivery of antiprogestins
LT2012006A (lt) 500 mg dozės fulvestrantas, skirtas išplitusio krūties vėžio gydymui
IN2012DE00138A (cg-RX-API-DMAC10.html)
Boisen et al. Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): promise and challenges
NZ742470A (en) Combination therapy for cancer